Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer

URN:NBN:SI:doc-BXYOCVFS2013Tuzi, Alessandrodocuments/doc/B/URN_NBN_SI_doc-BXYOCVFS_001.pdfdocuments/doc/B/URN_NBN_SI_doc-BXYOCVFS_001.txt147articlestr. 57-62, IV1318-2099269057792URN:NBN:SI:doc-BXYOCVFSengAssociation of Radiology and OncologyRadiology and oncology (Ljubljana)BYbreastdojkekemoterapijarak (medicina)therapyzdravljenjeEpirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancerfindings from two successive phase II studies